Europe’s Health‑Technology Assessment Landscape Is Shifting – What It Means for Patients and Pharma
From the moment the European HTA Regulation entered into force, member‑state agencies have been racing to harmonise clinical assessments across borders. The Spanish Agency for Medicines and Health Products (AEMPS) has just taken a historic step by joining a Joint Clinical Assessment (JCA) as a co‑evaluator. This move signals three emerging trends that will shape the future of health‑technology assessment (HTA) in Europe.
1️⃣ Greater Cross‑Border Collaboration in Clinical Evidence Review
With twelve JCAs already underway, the EU is creating a single “evaluation pipeline” that reduces duplicated work in each country. By sharing data, methodologies, and timelines, agencies can issue a single, harmonised clinical report that all 27 member states accept.
- Real‑life example: The ongoing JCA for ensartinib, an ALK‑inhibitor for advanced non‑small‑cell lung cancer (NSCLC), already features input from Spain, France, Italy and the Netherlands. Early coordination of PICOs (Population, Intervention, Comparator, Outcomes) means the final report will reflect the therapeutic realities in each market.
- Data point: A 2023 EU HTA Survey found that 78 % of national agencies consider JCAs “essential” for speeding up market access.
2️⃣ Patient‑Centred Evidence Generation Becomes the Norm
The new HTA model puts patients at the centre of assessment. AEMPS, for instance, is actively transmitting Spanish patient‑needs into JCA scope definitions. This ensures that outcomes most relevant to patients—such as quality‑of‑life metrics or real‑world adverse‑event data—are weighted alongside traditional efficacy endpoints.
Pro tip: Companies that embed patient‐reported outcome (PRO) measures early in their trial design are now seeing a 15‑20 % faster time‑to‑reimbursement in countries that adopt JCA pathways.
3️⃣ Digital Platforms Will Accelerate Evidence Synthesis
Artificial intelligence‑driven literature‑review tools and interoperable data‑exchange standards are being piloted across the HTA network. By 2027, the EU expects a “single‑source” digital repository where every submitted dossier is instantly searchable by all participating agencies.
According to a 2024 NICE technical report, agencies that used AI‑assisted systematic reviews reduced their assessment time by an average of 30 %.
What These Trends Mean for Stakeholders
For Pharmaceutical Companies
- Prepare uniform dossiers that meet the pan‑European JCA template.
- Invest in robust PRO data and real‑world evidence (RWE) from the outset.
- Adopt AI tools for rapid literature synthesis to stay ahead of evaluation timelines.
For Healthcare Professionals
Clinicians will receive clearer, harmonised guidance on new therapies, reducing confusion caused by divergent national recommendations. This enables faster adoption of breakthrough treatments like ensartinib for ALK‑positive NSCLC.
For Patients
Faster, consistent approvals translate into earlier access to innovative medicines, while patient‑centric outcome measures ensure that approved treatments truly address everyday needs.
Frequently Asked Questions
What is a Joint Clinical Assessment (JCA)?
A JCA is a collaborative clinical evaluation conducted by multiple EU HTA bodies, resulting in a single evidence report that all participating countries can use for reimbursement decisions.
How does AEMPS’s role as a co‑evaluator influence the assessment?
As a co‑evaluator, AEMPS contributes scientific expertise, ensures Spanish patient perspectives are considered, and helps harmonise the final report with national health‑system priorities.
Will JCAs replace national HTA processes?
Not entirely. JCAs provide the clinical evidence component, but each country may still conduct its own economic and budget impact analysis before final reimbursement.
How can companies prepare for the JCA process?
Submit dossiers that align with the European HTA template, integrate high‑quality PRO and RWE data, and engage early with national agencies to shape the PICOs.
What’s Next?
The EU’s HTA ecosystem is still evolving. Expect the number of JCAs to double by 2028, with more therapeutic areas—such as rare diseases and advanced therapies—joining the collaborative fold. Keeping an eye on the evolving guidelines published by the European Medicines Agency (EMA) will be crucial for staying ahead.
Stay informed! Subscribe to our newsletter for the latest updates on European HTA, upcoming JCAs, and actionable strategies for market access. Join now and never miss a beat.
Explore more on our site:
